• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.3910 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
September 06, 2024
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
September 05, 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
September 05, 2024
Via Investor Brand Network
News headline image
Lexaria Releases Strategic Letter from the Outgoing CEO
September 05, 2024
Via ACCESSWIRE
News headline image
Lexaria Welcomes Industry Veteran as New CEO
September 05, 2024
Via ACCESSWIRE
News headline image
First Results from Lexaria's Second GLP-1 Human Pilot Study
August 27, 2024
Via ACCESSWIRE
News headline image
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
August 22, 2024
Via ACCESSWIRE
News headline image
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
August 21, 2024
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
September 03, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
September 03, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
September 02, 2024
 
Via Benzinga
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
August 29, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
Positive Results from Lexaria's Molecular Characterization Study
August 19, 2024
Via ACCESSWIRE
News headline image
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
August 29, 2024
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
August 27, 2024
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
August 27, 2024
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
August 26, 2024
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via Investor Brand Network
Topics Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control
August 21, 2024
Via Investor Brand Network
Topics Animal Testing Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via Investor Brand Network
Topics Regulatory Compliance
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via CannabisNewsWire
Topics Regulatory Compliance
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
August 16, 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment
August 16, 2024
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program
August 12, 2024
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
August 08, 2024
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
August 08, 2024
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study
August 06, 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study
July 31, 2024
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
July 22, 2024
Via CannabisNewsWire
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap